Article Text

other Versions

PDF
Double-blinded infliximab dose escalation in patients with rheumatoid arthritis
  1. Mahboob U Rahman
  1. Centocor Research and Development, Inc, Malvern, PA, United States
    1. Ingrid Strusberg
    1. Centro Reumatologico Strusberg, Cordoba, Argentina
      1. Piet Geusens
      1. University Hospital Maastricht and University Hasselt, Campus Diepenbeek, Diepenbeek, Belgium, Netherlands
        1. Alberto Berman
        1. Hospital Angel C. Padilla, Tucuman, Argentina
          1. David Yocum
          1. University of Arizona, Tucson, AZ, United States
            1. Daniel Baker
            1. Centocor Research and Development, Inc, Malvern, PA, United States
              1. Carrie Wagner
              1. Centocor Research and Development, Inc, Malvern, PA, United States
                1. John Han
                1. Centocor Research and Development, Inc, Malvern, PA, United States
                  1. Rene Westhovens (rene.westhovens{at}uz.kuleuven.ac.be)
                  1. UZ Gasthuisberg, Leuven, Belgium

                    Abstract

                    Objective: To determine the efficacy, safety, and pharmacokinetics of infliximab dose escalation in patients with rheumatoid arthritis (RA) who had an inadequate response to 3 mg/kg infliximab treatment or flared after initially responding.

                    Methods: Patients with active RA, despite receiving methotrexate (MTX), received infliximab 3 mg/kg at weeks 0, 2, 6, and 14 in one of the three arms of the START trial. Beginning at week 22, patients had their infliximab dose increased in a double-blind fashion in increments of 1.5 mg/kg if the total tender and swollen joint count did not improve by at least 20% from baseline (lack of response) or the improvement at week 22 or later worsened by 50% or more (criterion for flare).

                    Results: Of the 329 evaluable patients, 100 (30.4%) patients required dose escalation at or after week 22 because of flare or lack of response. The majority of patients (> 80%) who received up to 3 dose escalations showed „d 20% improvement in the total tender and swollen joint count after their last dose escalation. Patients who required dose escalations generally had lower pre-infusion serum infliximab concentrations than those who did not require dose escalations. The incidences of adverse events and serious adverse events for the patients who received dose escalation(s) were similar to those of patients who did not receive dose escalation.

                    Conclusion: Less than one third of patients required a dose escalation. The majority of patients showed improvement after receiving increased doses of infliximab, without an increased risk of adverse events.

                    • dose escalation
                    • infliximab
                    • rheumatoid arthritis
                    • tumor necrosis factor-alpha

                    Statistics from Altmetric.com

                    Request permissions

                    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.